A cluster randomized controlled trial on a procedure to ensure appropriate management of medications with strong teratogenicity.

A cluster randomized controlled trial on a procedure to ensure appropriate management of medications with strong teratogenicity. - A cluster randomized controlled trial on a procedure to ensure appropriate management of medications with strong teratogenicity.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000042166

Enrollment

900

Registered

2020-10-19

Start date

2020-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple myeloma

Interventions

Understanding the Noveltability of Thalidmid(Non-extended groups) Understanding the Noveltability of Thalidmid(extended groups)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Men over 20 years of age and pregnant women treating thalidmid drugs in patients with multiple myeloma

Exclusion criteria

Exclusion criteria: Female patients with no possibility of pregnancy

Design outcomes

Primary

Measure	Time frame
Confirmation that all subjects and their partners do not report pregnancy Percentage of correct answers (correct answers to all questions of questionnaire 7 questions) of the understanding questionnaire (Appendix) at 24 weeks	—

Countries

Japan

Contacts

Public Contactrena tazawa

Japanese Red Cross Medical Center Medical Secretary's Division

iryohisyoka2@med.jrc.or.jp03-3400-1311

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026